The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Sellas Life Sciences Group Inc. (NASDAQ:SLS) is one of the 9 Stocks Winning by Double Digits.

Sellas Life Sciences extended its winning streak to a 6th straight session on Thursday, climbing 14.83 percent to end at $10.53 apiece, following a regulatory filing that hinted at a potential acquisition.

In a disclosure, Sellas Life Sciences Group Inc. (NASDAQ:SLS) announced that it made changes to its employment and severance agreements with three of its executive members, namely President and CEO Angelos Stergiou, Chief Finance Officer John Burns, and Chief Development Officer Dragan Cicic, under which they would receive lump sum payment benefits in case of a "change of control."

Photo by Tima Miroshnichenko on Pexels

Burns and Cicic are set to receive lump sum payments equal to 15 months of their base salary, target bonus for the year of termination, and immediate vesting of unvested shares, among others, in case they are terminated by new company owners.

Investors believed the amendments were in preparation for a potential takeover, ahead of Sellas Life Sciences Group Inc.'s (NASDAQ:SLS) looming results of its phase 3 clinical study of its therapy candidate for acute myeloid leukemia (AML).

Last month, Sellas Life Sciences Group Inc. (NASDAQ:SLS) said that it would provide updates to the late-stage study as soon as it reaches its pre-determined 80th patient date, data from which it deemed already enough to analyze results on whether or not its Galinpepimut-S (GPS) treatment candidate made a meaningful improvement to patients versus those in the placebo group.

As of last month, the company had 78th patient deaths.

While we acknowledge the potential of SLS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.